Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism

Our in vitro results represent the first evidence that Notch3 silencing in combination with chemotherapeutics could conceivably provide a novel strategy for HCC treatment that deserves further exploration.